From Local Innovation to Global Expansion: How Chinese Enterprises Tell China's Story on the International Stage

Unstoppable Domestic Substitution: Moving Beyond "Made in China" to "Intelligently Made in China"

Over the past several years, China’s medical industry has primarily pursued innovation through tracking and imitation. By following a pathway of introducing, digesting, absorbing, and re-innovating foreign technologies, the sector has continuously narrowed the gap with developed countries, achieving domestic growth and import substitution in certain areas. Nevertheless, overcoming critical technological bottlenecks remains a formidable challenge in many specialized fields.

During the 14th Five-Year Plan period, China’s medical industry will further accelerate its development toward domestication, high-end positioning, and brand building. How enterprises adapt to the sweeping trends of informatization, intelligence, networking, and digitalization is a key reflection of their core competitiveness. Guided by national macro policies vigorously promoting innovative development in biomedicine, China has gradually transitioned from an initial follower in innovation to a leader. A cohort of local enterprises committed to independent innovation has emerged, steadily moving beyond “Made in China” toward “Intelligently Made in China.”

This conference features 20+ specialized forums, spanning from brain science to cardiovascular health, and from rehabilitation robotics to life science tools, forAdvances in the Application of Brain-Computer Interface Technology, Building International Brands for Cardiovascular and Cerebrovascular Implantable and Interventional Medical Devices, Rehabilitation Robots and Cloud Service Platforms, Innovative Applications of Artificial Intelligence in Medical Imaging, Current Status and Development Trends of Medical AI in Cardiac Health Diagnosis and Treatment, How Specialized CDMOs Efficiently Empower Biopharmaceutical Companies to Go Global, Pace and Pathway of Localizing the Biopharmaceutical Supply Chain, and the Journey and Prospects of Domestic Life Science Reagent EnterprisesConduct in-depth discussions on trending topics, inviting representatives from multiple companies that integrate the application of new technologies with innovations in healthcare and pharmaceutical services to jointly explore the value opportunities in China’s intelligent healthcare industry.

CooperationGlobal Strategy: Diagnosing International Shifts, Listening to the World’s Voice

This conference featured broader international participation, fostering global dialogue and exchange through roadshows, roundtables, and speeches. Focusing on the three pillars of venture capital, innovation, and cutting-edge advancements, the event aimed to build consensus and pool expertise to chart future development strategies and directions for China at this critical juncture.

International practice has proven that innovative development is closely linked to capital investment, and the conference jointlyEmbassy of Canada in China, UK Department for International Trade, Flemish Investment and Trade Agency of the Consulate-General of Belgium in Shanghai, New* Research Enterprise Cooperation CenterJointly OrganizedGlobal Healthcare Innovation Project Pitch Event, with each country serving as a dedicated sub-session, to enrich the international healthcare venture capital ecosystem by continuing to bridge investors and entrepreneurs, thereby empowering healthcare companies to engage and interact with leading investment institutions.

In recent years, digital therapeutics have ignited industry attention,WorkAs one of the earliest to focus on digital therapeutics,VCBeatAs early as 2016, we began focusing on digital therapeutics, and this time we have further collaborated withDigital Therapeutics Alliance（DTA，Digital Therapeutics Alliance）、Weimai(Co-Chair of the DTA Asia-Pacific Policy Research Center) Jointly translated and released《DTX Value Assessment and Integration Guide》Chinese Version, and invitedDTA Founder and Current DTA Chief Policy Officer Megan CoderParticipate in the roundtable discussion to comprehensively and timely showcase the development and exploration of digital therapeutics globally and in China, providing references for industry advancement.

Meanwhile, we have also invited numerous top experts with a global perspective, includingXu Fu, Deputy Director of the Bill & Melinda Gates Foundation Beijing Representative Office (Head of Health Innovation and Partnerships)Clean；Barun Dutta, Chief Scientist at IMEC-STS; Peter Peumansec, CTO of Life Sciences at imec; Dr. Tao Du, Chairman of the Society of FDA Experts, former Senior Review Officer at the FDA, and Chairman of Eglin Pharmaceuticals; Dr. Ning Li, former Director of Review and Division Director at the FDA, and CEO of Junshi Biosciences; Dr. Tianzi Jiang, Director of the Brain Network Group Research Center at the Institute of Automation, Chinese Academy of Sciences, and Foreign Member of the Academia Europaea; Jeffrey Bernstein, Senior Vice President of UPMC International and Managing Director for China; and Cedric Wu, Vice President of the GenScript Innovation Centerand so on, helping domestic companies understand cutting-edge international information and promptly address challenges encountered in global operations, thereby smoothing the path for their “going global” initiatives.

Cross-Border Expansion Is Timely: Stepping onto the Global Stage and Telling China’s Story Well

Amid recurring epidemic outbreaks, 2022 presented both challenges and opportunities. On one hand, with the successful global expansion of BeiGene’s zanubrutinib and Legend Biotech’s BCMA-targeted CAR-T therapy, ciltacabtagene autoleucel, the surge in Chinese clinical trials in 2022 began to translate into corresponding New Drug Applications (NDAs) submitted to the U.S. Food and Drug Administration (FDA). However, given the FDA’s stringent requirements for international multi-center clinical trials, the path for domestically developed innovative drugs to enter overseas markets remains arduous. On the other hand, the pandemic accelerated the global expansion of medical devices. According to statistics from the China Chamber of Commerce for Import and Export of Medicines and Health Products, exports of medical devices accounted for 54.2% of China’s total medical product exports in 2021, representing half of the country’s medical product export trade for two consecutive years.

Behind the bustling wave of global expansion lies the active support of the state in building a multi-stakeholder, multi-dimensional framework for external publicity. For companies going global, the key lies in how to effectively tell China’s story and implement their internationalization strategies. So, for Chinese medical enterprises that are experiencing both rapid, unregulated growth and steadfast progress, what path will domestic pharmaceutical companies take in their future explorations?“How Should Companies Steer Their ‘Global Expansion’ Strategy?”The pharmaceutical companies that previously “went global,” either achieving success or encountering obstaclesWhat Are the Key Lessons Learned from Global Expansion?？What Should an Innovation Pathway Structured from a Global Perspective Look Like?

In response to these issues, we are honored to have invited executives from RemeGen, Junshi Biosciences, X-Novo Therapeutics, Weimou Biotech, Zhongsheng Suyuan, Lepu Biopharma, Takeda, and other leading companies to share their insights at this Cloud Top 100 Conference.International Practices in New Drug Development and China’s Experience; Innovation and Globalization of Multi-Target Biologics; Strategic Transformation of China’s Biopharmaceutical Industry; AI- and Automation-Driven New Drug Development Amid the Pandemic; Digitalization Leading MedTech, Globalization Winning International Markets; Chinese Pharmaceutical Companies’ Innovative Path to Expanding into Southeast Asiasuch topics.

Top 100 Future Healthcare Online Conference, featuring forums across 20+ specialized sectors and gathering 200+ leading experts from academia, industry, research, healthcare, and investment. From June 14 to 18, 2022, let us seize the forefront of hot topics and join this grand event that brings together the medical and health industries!

Contributing Editor: Zou Ling